Skip to main content
. 1996 Jan;11(1):58–68. doi: 10.3904/kjim.1996.11.1.58

Fig. 1.

Fig. 1.

Survival curves for the 30 patients receiving α-IFN plus cis-platinum and the 26 patients receiving no antitumor therapy.